Fennec Pharmaceuticals Inc. (FENC) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Contrasting side by side

Both Fennec Pharmaceuticals Inc. (NASDAQ:FENC) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are Biotechnology companies, competing one another. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fennec Pharmaceuticals Inc. N/A 0.00 9.19M -0.51 0.00
Brainstorm Cell Therapeutics Inc. N/A 0.00 8.29M -0.42 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Fennec Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 represents Fennec Pharmaceuticals Inc. (NASDAQ:FENC) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals Inc. 0.00% -36.7% -34.7%
Brainstorm Cell Therapeutics Inc. 0.00% -101.8% -59.6%

Volatility & Risk

A -0.44 beta means Fennec Pharmaceuticals Inc.’s volatility is 144.00% less than Standard and Poor’s 500’s volatility. Brainstorm Cell Therapeutics Inc.’s 56.00% more volatile than Standard and Poor’s 500 which is a result of the 1.56 beta.

Liquidity

The current Quick Ratio of Fennec Pharmaceuticals Inc. is 12 while its Current Ratio is 12. Meanwhile, Brainstorm Cell Therapeutics Inc. has a Current Ratio of 3.3 while its Quick Ratio is 3.3. Fennec Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Brainstorm Cell Therapeutics Inc.

Insider & Institutional Ownership

Fennec Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. has shares held by institutional investors as follows: 56.2% and 11.8%. Insiders held roughly 0.1% of Fennec Pharmaceuticals Inc.’s shares. Insiders Comparatively, held 11.2% of Brainstorm Cell Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Fennec Pharmaceuticals Inc. -7.76% -18.25% -28.22% -43.92% -31.26% -38.32%
Brainstorm Cell Therapeutics Inc. -3.54% -5.49% -27.36% -34.78% -25.37% -23.47%

For the past year Fennec Pharmaceuticals Inc.’s stock price has bigger decline than Brainstorm Cell Therapeutics Inc.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.